A novel CT contrast agent for intestinal-targeted imaging through rectal administration

In this study, a novel CT contrast agent used by rectal administration is developed for targeting intestinal imaging. Iopamidol, an iodinated contrast agent, is loaded in chitosan (CS) nanospheres modified by Anti-5-HT3R (AH) antibody. The obtained AH-CS-I nanospheres (AH-CS-I Ns) would combine to 5...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Zhu Jingyao, Weng Hao, Xie Shichen, Cheng Jiejun, Zhu Jun
Formato:	article
Lenguaje:	EN
Publicado:	De Gruyter 2021
Materias:	chitosan nanospheres anti-5-ht3r ct imaging iopamidol intestinal-targeted Polymers and polymer manufacture TP1080-1185
Acceso en línea:	https://doaj.org/article/c11d17888d9c4840bb6adcdfa109bf66
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:c11d17888d9c4840bb6adcdfa109bf66
record_format	dspace
spelling	oai:doaj.org-article:c11d17888d9c4840bb6adcdfa109bf662021-12-05T14:10:48ZA novel CT contrast agent for intestinal-targeted imaging through rectal administration1618-722910.1515/epoly-2021-0076https://doaj.org/article/c11d17888d9c4840bb6adcdfa109bf662021-10-01T00:00:00Zhttps://doi.org/10.1515/epoly-2021-0076https://doaj.org/toc/1618-7229In this study, a novel CT contrast agent used by rectal administration is developed for targeting intestinal imaging. Iopamidol, an iodinated contrast agent, is loaded in chitosan (CS) nanospheres modified by Anti-5-HT3R (AH) antibody. The obtained AH-CS-I nanospheres (AH-CS-I Ns) would combine to 5-HT3 receptors highly expressed on the gastrointestinal mucosal, enhancing the intestinal-targeting ability of the contrast agent. The AH-CS-I Ns were administered by the rectal route for intestinal CT imaging, and FITC-labeled AH-CS-I Ns were prepared for investigating the in vivo distribution of the contrast agent. As a result, obvious contrast enhancement could still be observed at 6 h post administration because of the poorly absorption of enteral AH-CS-I Ns. Unlike the intravascularly administered agents, AH-CS-I Ns would not accumulate in the kidney and induce adverse reactions. Therefore, this technology has potential applications in the examination of intestinal diseases and could reduce the side effect of commercial iopamidol.Zhu JingyaoWeng HaoXie ShichenCheng JiejunZhu JunDe Gruyterarticlechitosan nanospheresanti-5-ht3rct imagingiopamidolintestinal-targetedPolymers and polymer manufactureTP1080-1185ENe-Polymers, Vol 21, Iss 1, Pp 754-762 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	chitosan nanospheres anti-5-ht3r ct imaging iopamidol intestinal-targeted Polymers and polymer manufacture TP1080-1185
spellingShingle	chitosan nanospheres anti-5-ht3r ct imaging iopamidol intestinal-targeted Polymers and polymer manufacture TP1080-1185 Zhu Jingyao Weng Hao Xie Shichen Cheng Jiejun Zhu Jun A novel CT contrast agent for intestinal-targeted imaging through rectal administration
description	In this study, a novel CT contrast agent used by rectal administration is developed for targeting intestinal imaging. Iopamidol, an iodinated contrast agent, is loaded in chitosan (CS) nanospheres modified by Anti-5-HT3R (AH) antibody. The obtained AH-CS-I nanospheres (AH-CS-I Ns) would combine to 5-HT3 receptors highly expressed on the gastrointestinal mucosal, enhancing the intestinal-targeting ability of the contrast agent. The AH-CS-I Ns were administered by the rectal route for intestinal CT imaging, and FITC-labeled AH-CS-I Ns were prepared for investigating the in vivo distribution of the contrast agent. As a result, obvious contrast enhancement could still be observed at 6 h post administration because of the poorly absorption of enteral AH-CS-I Ns. Unlike the intravascularly administered agents, AH-CS-I Ns would not accumulate in the kidney and induce adverse reactions. Therefore, this technology has potential applications in the examination of intestinal diseases and could reduce the side effect of commercial iopamidol.
format	article
author	Zhu Jingyao Weng Hao Xie Shichen Cheng Jiejun Zhu Jun
author_facet	Zhu Jingyao Weng Hao Xie Shichen Cheng Jiejun Zhu Jun
author_sort	Zhu Jingyao
title	A novel CT contrast agent for intestinal-targeted imaging through rectal administration
title_short	A novel CT contrast agent for intestinal-targeted imaging through rectal administration
title_full	A novel CT contrast agent for intestinal-targeted imaging through rectal administration
title_fullStr	A novel CT contrast agent for intestinal-targeted imaging through rectal administration
title_full_unstemmed	A novel CT contrast agent for intestinal-targeted imaging through rectal administration
title_sort	novel ct contrast agent for intestinal-targeted imaging through rectal administration
publisher	De Gruyter
publishDate	2021
url	https://doaj.org/article/c11d17888d9c4840bb6adcdfa109bf66
work_keys_str_mv	AT zhujingyao anovelctcontrastagentforintestinaltargetedimagingthroughrectaladministration AT wenghao anovelctcontrastagentforintestinaltargetedimagingthroughrectaladministration AT xieshichen anovelctcontrastagentforintestinaltargetedimagingthroughrectaladministration AT chengjiejun anovelctcontrastagentforintestinaltargetedimagingthroughrectaladministration AT zhujun anovelctcontrastagentforintestinaltargetedimagingthroughrectaladministration AT zhujingyao novelctcontrastagentforintestinaltargetedimagingthroughrectaladministration AT wenghao novelctcontrastagentforintestinaltargetedimagingthroughrectaladministration AT xieshichen novelctcontrastagentforintestinaltargetedimagingthroughrectaladministration AT chengjiejun novelctcontrastagentforintestinaltargetedimagingthroughrectaladministration AT zhujun novelctcontrastagentforintestinaltargetedimagingthroughrectaladministration
_version_	1718371744473939968

A novel CT contrast agent for intestinal-targeted imaging through rectal administration

Ejemplares similares